Menu

Board of Directors

Dror Ben-Asher , Chairman

Dror Ben-Asher co-founded RedHill and serves as the Company's CEO and Chairman, bringing extensive managerial and transactional expertise. He was previously with ProSeed Capital, a European corporate finance boutique. Dror is a graduate of the University of Oxford (M.Jur.) and completed his LL.M. studies at Harvard University. At Harvard, Dror was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror received an LL.B. with distinction (First Class Honors) from the University of Leicester.

Dan Suesskind , Director

Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently. Mr. Suesskind also serves as a board member at Migdal Group (one of Israel’s leading insurance and finance groups), Gefen Biomed Investment (TASE: GEFEN), NESS Technologies (NASDAQ: NSTC), Syneron Medical (NASDAQ: ELOS) and the Jerusalem Foundation. He holds a BA in economics and political science from the Hebrew University and an MBA from the University of Massachusetts. Mr. Suesskind is a member of the Israeli Forum of Chief Financial Officers and was awarded the “Life Time Achievement Award” from that forum in 2007.

Eric Swenden , Director

Mr. Swenden had a long and successful career in finance and company management. He held various senior positions in companies including Vandemoortele Food Group and General Bank (Fortis) and Lifeline Scientific (current).

Kenneth Reed MD , Director

Dr. Reed is an experienced physician and director. He is currently with Kenneth Reed M.D. P.C. (Dermatologist) and Minerva Biotechnologies. Dr. Reed was also a Clinical Investigator for companies including Amgen, Astellas and Centocor (J&J). He is a graduate of Harvard Medical School (residency in dermatology), Thomas Jefferson University Hospital (medical internship), College of Medicine and Dentistry of New Jersey (M.D.) and Brown University (B.A.).

Rick D. Scruggs , Director

With over 25 years of experience in the pharmaceutical industry, Mr. Scruggs has extensive knowledge in commercial operations and business development. He most recently served as Executive Vice President of Business Development at Salix Pharmaceuticals, Ltd., up to its acquisition by Valeant Pharmaceuticals International earlier this year. Mr. Scruggs joined Salix in 2000, after working at Oclassen Pharmaceuticals Inc. and Watson Pharmaceuticals, and helped build Salix’s commercial organization, serving in various sales and commercial trade related positions. He was appointed as Executive Vice President in 2011 and was responsible for all business development activities as well as the worldwide distribution of Salix innovative products and intellectual property. Mr. Scruggs also served as the Head of the Board of Directors of Oceana Therapeutics, Salix’s European subsidiary.

Shmuel Cabilly PhD , Director

Mr. Cabilly is a highly regarded scientist and an experienced director. He was previously with several companies including Ethrog Biotech (Co-Founder and Chief Scientist) which was sold to Invitrogen. He graduated from the Hebrew University (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production.

Ofer Tsimchi , Director

Mr. Tsimchi has many years of business experience in various executive positions. Mr. Tsimchi is the co-founder and manager of Danbar Group and serves as the Chairman of Polysack (TASE: PLSK). Mr. Tsimchi served as a board member of several companies including, among others, Tefron (TASE:TFRN) and Kapro Industries Ltd. (present). Mr. Tsimchi holds a B.Sc. in Economics and Agriculture from the Hebrew University of Jerusalem.

Nurit Benjamini , Director

Ms. Benjamini is a senior executive with over 20 years’ experience serving as Chief Financial Officer in various leading organizations and extensive knowledge and experience in financing and security regulations. She previously served as CFO of Wix.com Inc., Coppergate Communications Ltd. and Compugen Ltd. Ms. Benjamini currently serves as CFO of Tabtale and a Director at BioLineRx Ltd. and Allot Communications.

Nicolas Weinstein , Director

Mr. Weinstein has served as Managing Director of Water Bear Investments LLC since January 2017 and also leads the healthcare and venture investments of EMC2 Fund Ltd. and its partnership interests in Olive Tree Ventures Limited Partnership (Israel) and Puma Bioventures (a U.S. biotech fund). Mr. Weinstein previously served as country head in Chile for Abbott Laboratories / CFR Pharmaceuticals and also held VP Business Development and VP Marketing & Sales positions at CFR Pharmaceuticals. Mr. Weinstein holds an M.Sc. in Finance from Universidad Adolfo Ibanez (Chile) and an MBA from the Kellogg School of Management (2012).